The overall cure rate of colon cancer has not improved dramatically in the last decade, remaining at approximately 60% S-year survival. The main reason for this lack of progress is that at the moment the primary tumour is resected, a significant proportion of the patients with seemingly localised disease already has (undetectable) micrometastases, mostly in the liver. The most important prognostic indicators have been extension of the tumour into the bowel wall and the presence of lymph node metastasis, as expressed in the Dukes classification. However, in the Dukes B and C categories, these parameters are poor predictors of final outcome. For improvement of the prognosis, in addition to earlier detection, more aggressive (adjuvant) treatment of high risk patients would be a rational strategy. This requires development of new therapeutic modalities, but also reliable stratification of patients according to high risk or low risk for recurrent disease. In recent years, many attempts have been made to improve the prediction of final outcome. Parameters studied include inflammatory response to the primary tumour, tumour cell growth fraction, turnout cell differentiation, genetic abnormalities and expression of genes involved in invasion and metastasis. Although some of these newer parameters have significant predictive value, in multivariant analyses, most appear to have limited independent value. Recent studies indicate that genetic abnormalities might be important new prognostic indicators. One of the most promising findings in this area is an allelic loss of chromosome 18q, which allows division of Dukes B patients into subgroups with low risk and high risk for recurrent disease.
INTRODUCTION
IN THE clinical management of colorectal cancer, the pathologist plays a distinct role. During the diagnostic evaluation of a putative colorectal carcinoma patient, it is the pathologist who makes the final diagnosis, usually on an endoscopic biopsy specimen. This diagnosis will be confirmed through examination of the resection specimen. Of more importance than diagnostic confirmation is the determination of the extent of spread in the bowel wall and in regional lymph nodes. This information is indispensible for staging purposes. Staging is still mostly performed according to the Dukes classification, although the use of a TNM based staging system is becoming more popular. Tumour stage is the most important prognostic parameter. The predictive value of tumour stage, especially in the Dukes B and C categories (which correspond to stages II and III), is rather limited. Therefore, pathologists have explored a variety of possibilities to develop more detailed classification parameters, which would allow reliable prediction of tumour behaviour in the individual patient. Thus, in numerous studies, the prognostic significance of cancer cell differentiation, proliferative activity, expression of invasion and metastasis-related genes and genetic changes, including oncogene and tumour suppressor gene abnor-malities, have been investigated.
It is the purpose of this brief review to critically examine the significance of these new parameters for the clinical management of colorectal cancer.
CONVENTIONAL STAGING
It is generally recognised that tumour stage, as reflected for example in the Dukes classification, is one of the most powerful predictors of final outcome in colorectal cancer patients [ 11. The overall S-year survival rate of patients with colorectal cancer is approximately 60%. However, this differs greatly for the different stages ( 35% of patients, S-year survival is 70% and for Dukes C (about 50% of patients) this is approximately 30%. The lack of prognostic precision in stages B and C hampers stratification of patients into subgroups which might benefit from additional adjuvant therapy. Pathologists have responded to this problem by introducing new parameters which might have independent prognostic significance. More detailed histological evaluation of the pattern of invasion into the bowel wall or into veins has been advocated. Hase and associates [2] reported that irregular tumour cell budding at the invasive front of the tumour indicates more aggressive behaviour than a straight "pushing" tumour margin. Patients with a budding tumour margin showed 20% Syear survival against 70% in patients without budding. Budding frequency rose with Dukes stage, but, when stratified for stage budding remained an independent prognostic variable. Yamazoe and associates [3] investigated the depth of venous invasion as a predictor for liver metastasis. This parameter appeared to predict the occurrence of liver metastasis with high probability, especially in combination with desmoplastic reaction, lymphocytic infiltration and depth of invasion. The extent of lymphocytic infiltration was also taken into account in the classification proposed by Shepherd and associates [4] . The latter classification has gained some popularity, but has not become generally accepted. An important limitation of classifications based upon detailed histopathological criteria is their lack of reproducibility. Parameters, such as depth of venous invasion, budding and even intensity of lymphocytic infiltrate are often difficult to quantitate and, therefore, rather subjectively scored.
An alternative approach towards more refined histopathological classification of tumour stage has been the detailed search for lymph node micrometastases by immunohistochemistry. It has been proposed that carcinomas with endocrine cells consist of relatively primitive pluripotent cells which might be more aggressive. Alternatively, neurohormonal peptide production in a carcinoma might provide a paracrine growth stimulus.
TUMOUR CELL PROLIFERATION
In most malignant neoplasms, a correlation appears to exist between proliferative activity in the tumour and patient survival. Proliferative activity can be histologically assessed by counting mitoses, but because the M-phase is only a very short window in the total cell cycle, mitotic counts appear to be somewhat inaccurate.
More recent approaches encompass the determination of S-phase fraction by DNA-flow cytometry, metabolic labelling of DNA-synthesising cells using [3H]thymidine [lo] or bromodeoxyuridine and immunohistochemical staining of cell cycle related gene expression. Popular cell cycle-related antigens are proliferative cell nuclear antigen (PCNA, a DNA polymerase related protein [ 111) and the Ki67 antigen. The flow cytometric determination of S-phase fraction seems to be a relatively simple measure of proliferative activity. This technique, however, has two important limitations. Firstly, in carcinomas with multiple aneuploid stemlines in addition to diploid cells, it is not easy to determine the S-phase fraction on the basis of solid criteria. Secondly, most flow cytometric analyses are performed on material retrieved from paraffin sections [ 121. The precision of DNA measurement is limited in this type of material, and hence reliable S-phase fractions cannot be determined. In spite of these limitations, correlations between S-phase fraction and tumour behaviour have been found. Schutte and colleagues [ 131 reported a worse outcome in Dukes B patients with an S-phase fraction exceeding 15%.
A much more popular approach towards proliferation analysis is immunohistochemical staining for PCNA or the Ki67 antigen. The latter is the favoured technique since, with the introduction of the MIB-1 antibody, this antigen can also be stained in paraffin sections (Figure 1 ). Mayer and associates [ 141 and AlShebener and associates [ 151 recently reported on the prognostic significance of PCNA expression. In both studies, a multivariant analysis was included. The data indicate that the percentage of PCNA positive cells is an independent predictor of tumour behaviour, the higher PCNA index indicating a shorter survival. Silvestrini and colleagues [lo] showed, by [3H]thymidine labelling of metastatic colon cancer cells in the liver, that even when liver metastases are present cell proliferation may be a useful prognostic marker. Thus, proliferative activity as reflected in a PCNA index or (preferably) a Ki67 index (using the MIB-1 Havenith and associates [16] studied the prognostic significance of basement membrane staining in colorectal cancer. These investigators noted that, in the tumour periphery, cancer cells did not have a basement membrane, but in the tumour centre a variable amount of this material was deposited. Increasing basement membrane deposition correlated with better prognosis. These authors postulated that the host response to the tumour is reflected in the extent of deposition of extracellular matrix.
The prognostic value of the expression of matrix proteases was recently studied by Mulcahy and colleagues [18] and by Ganesh and colleagues [ 171. Mulcahy's group [ 181 stained colorectal cancer tissues for the urokinase type plasminogen activator (uPA). In Dukes B patients, high grade uPA staining indicated a high probability of the development of liver metastases. Ganesh and associates [ 171 measured levels of the different components of the plasminogen activator/plasmin system (including uPA, t(tissue type)PA, and the inhibitors PAI-and PAI-2) in normal and cancer tissue by immunoassay. These authors found the ratio of UPA in cancer tissue/tPA in normal mucosa and the PAIlevel in cancer tissue to be independent prognostic variables. It seems, therefore, that determination of matrix proteases might be useful in the development of new subclassifications of colorectal cancer with prognostic value. In search of new markers for metastatic disease, the ~223 gene has received wide attention (see MacDonald and associates, pp. 10961100). This gene was discovered through the generation of a monoclonal antibody which differentially labelled metastatic and non-metastatic melanoma cells. Recently, loss of the nm23 gene has been reported to correlate with the occurrence of distant metastases in colorectal cancer [19] . For colorectal cancer, the nm23 findings have been somewhat conllicting, however, and consequently this finding needs to be further confirmed.
Another area of promising development has been that of cell adhesion molecules. On the assumption that loss of intercellular adhesion would precede cancer cell invasion, the expression of the crucial epithelial cell adhesion molecule, E-cadherin, has been studied in colorectal cancer [20] . It has become clear that E-cadherin expression is highly correlated with tumour differentiation (Figure 2 ), and may not be an independent prognostic variable. Another limitation of E-cadherin as an invasion marker is that loss of expression of a few cells is much more difficult to detect (let alone to quantitate) than overexpression.
This limitation is not shared by the CD44 family of adhesion molecules. CD44 is widely expressed on leucocytes and serves as a leucocyte adhesion molecule, with a regulating function in leucocyte traffic. Following cloning of the CD44 gene, it was discovered that this gene can be alternatively spliced, which results in a family of related proteins derived from a single gene. Subsequent studies have shown that the variant (alternatively spliced) forms of the CD44 molecule are expressed in specific patterns on normal and neoplastic epithelial cells. The v6 variant was shown to be expressed on a subgroup of colorectal carcinomas (Figure 3) , and it was established that v6 expression is strongly correlated with tumour progression [21] . Although prospective testing of the clinical use of CD44 v6 staining is still not complete, it is expected that this might become an important new prognostic marker in colorectal cancer. 
TUMOUR CELL GENETICS No solid tumour has been studied as intensely as colorectal
cancer for molecular genetic abnormalities. The pioneering work of Vogelstein and collaborators led to the definition of a series of molecular genetic abnormalities which together determine the neoplastic phenotype of a colorectal cancer cell [22] . Although well accepted in cancer cell biology, the clinical use of this molecular genetic model of colorectal carcinogenesis remains to be established.
Clinical testing of gross genetic abnormalities, as reflected in an abnormal DNA content of the cancer cells which can be determined by DNA flow cytometry, has been reported repeatedly [23, 241. Ploidy analysis is relatively simple and fast, and could, therefore, be of practical use if it would provide a strong independent new predictor for prognosis. Most studies, to date, indicate that patients with aneuploid tumour cell populations, in general, have a shorter survival than patients with diploid tumours. Tumour ploidy, however, is signilicantly correlated with other prognostically relevant variables, including Dukes stage, tumour grade and proliferative activity, and, therefore, as an independent prognostic indicator, ploidy has appeared of limited value [23, 241. Although technically more complex, detailed molecular genetic analysis of colorectal cancer in search of prognostically relevant parameters could potentially yield highly valuable information which could be used in clinical management. Recent developments in this methodology have allowed the use of even paraffin-embedded archival material for molecular genetic analysis [25] . The oncogenes and tumour suppressor genes of interest for the study of colorectal cancer can be directly inferred from Vogelstein's model of colorectal carcinogenesis [22] . KI-RAS oncogene mutations are assumed to function early in colorectal carcinogenesis.
Consequently, KI-RAS mutations are found in a high percentage of colorectal cancers. It was even recently shown that in precancerous conditions as well as in inflammatory bowel disease without overt dysplasia ICI-RAS mutations may occur [26] . In spite of their putative early role in colorectal carcinogenesis, KT-JZAS mutations appeared to be independent predictors of unfavourable outcome in several studies [27, 281. Interesting observations on the pattern of mutations on codon 12 of the KZ-RAS were recently reported by Moerkerk and associates [28] . These authors observed only G->A mutations in Dukes B, but predominantly G-X or G->T mutations in Dukes C turnours. This observation suggests that a Dukes C tumour is not merely a later stage of progression of a Dukes B tumour, but possibly a different tumour subgroup with a different pathway of molecular carcinogenesis.
This possibility, however, needs to be confirmed. Bell and associates [27] In a PCR-based study, Hamelin and associates [29] convincingly demonstrated a strong correlation between the presence of TP53 mutations and shorter survival. In muhivariate analysis, this parameter appeared to be independent from other prognostic variables. Mutations of TP53 can also be detected by immunocytochemistry because the mutated proteins appear to have a prolonged half-life, which leads to their accumulation in the nuclei of mutated cells (Figure 4 ). Yamaguchi and colleagues [30] studied the prognostic significance of TP53 overexpression by immunocytochemistry. In primary tumours, TP53 expression was not correlated with any other histological variable. However, patients with a TP53 positive tumour showed a higher risk of developing liver metastases. Accordingly, in the Dukes C category, TP53 overexpression appeared to be a highly significant predictor of prognosis in terms of the 5-year survival rate. 
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In a recent study, Jen and colleagues [25] reported on the significance of allelic loss of chromosome 18q in colorectal cancer. These authors investigated 18q status using polymorphic microsatellite markers in a PCR-based assay on paraffinembedded tissue. Chromosome 18q was chosen in view of the fact that it is frequently deleted in colon cancer (hence the name of the associated oncogene: deleted in colon cancer or DCC). Of all turnours, 67% showed 18q allelic loss. With increasing stage, the frequency of allelic loss also increased. Tumours with allelic loss were often (70%) located in the right side of the colon. When stratified for stage, 18q allelic loss was strongly correlated with survival in stage II (which corresponds with Dukes B) patients. In fact, stage II patients could be divided according to 18q allelic loss into a subgroup which behaved as stage I (no loss) and a subgroup which behaved as stage III (loss). In view of the high probability of the existence of correlations between the different prognostic parameters, a multiple regression analysis was performed. In all models, 18q allelic loss had a highly significant independent effect on prognosis.
CONCLUSION In reviewing
the available data concerning pathological characteristics of colorectal cancer (Table 2) it is clear that conventional anatomical (depth of invasion, lymph node involvement, liver metastases) and histological parameters (vascular and perineural invasion, lymphocyte infiltration and to a lesser extent tumour differentiation) continue to provide a solid basis for the purposes of prognosis.
It is also clear, however, that improvement in the prognosis of colorectal carcinoma will have to come either from earlier detection and secondary prevention or from more effective therapy. For more effective therapy, adjuvant treatment modalities are available and more effective new modalities are being, or will be, developed. Reliable stratification of particularly Dukes B and C (or stages II and III) patients into subgroups with low and high risk of recurrent disease will be essential. This is where pathology will have its most significant impact on the clinical management of colorectal cancer. Prognostic factors, however, will only become clinically significant when they are used in clinical decision-making. The clinical use of prognostic factors should be assessed in 
